PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study.
Ziemssen T, Diaz-Lorente M, Abdelkader M, Cornelissen C
Mult Scler Relat Disord. 2014 Nov; 3(6):751. Epub 2014 Nov 21. PMID: 25891587.Abstract